Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD4-positive, alpha-beta T cell | 14 studies | 21% ± 4% | |
naive thymus-derived CD8-positive, alpha-beta T cell | 11 studies | 28% ± 8% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 10 studies | 28% ± 7% | |
regulatory T cell | 6 studies | 17% ± 1% | |
platelet | 6 studies | 25% ± 5% | |
oligodendrocyte | 6 studies | 24% ± 7% | |
basal cell | 5 studies | 25% ± 11% | |
CD8-positive, alpha-beta T cell | 4 studies | 24% ± 4% | |
endothelial cell | 4 studies | 20% ± 3% | |
CD4-positive, alpha-beta memory T cell | 4 studies | 21% ± 3% | |
T cell | 3 studies | 24% ± 4% | |
type B pancreatic cell | 3 studies | 31% ± 10% | |
epithelial cell | 3 studies | 22% ± 3% | |
effector memory CD4-positive, alpha-beta T cell | 3 studies | 22% ± 2% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 3 studies | 17% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 3525.79 | 328 / 328 | 100% | 28.48 | 178 / 178 |
prostate | 100% | 4037.23 | 245 / 245 | 100% | 48.98 | 502 / 502 |
skin | 100% | 2403.35 | 1808 / 1809 | 100% | 45.03 | 472 / 472 |
esophagus | 100% | 2208.37 | 1443 / 1445 | 100% | 26.37 | 183 / 183 |
uterus | 100% | 2024.57 | 170 / 170 | 100% | 36.60 | 457 / 459 |
thymus | 100% | 3387.87 | 653 / 653 | 100% | 33.18 | 602 / 605 |
breast | 100% | 2147.33 | 459 / 459 | 99% | 31.57 | 1112 / 1118 |
intestine | 100% | 2559.45 | 966 / 966 | 99% | 28.84 | 523 / 527 |
stomach | 100% | 2048.16 | 359 / 359 | 99% | 25.00 | 283 / 286 |
lung | 100% | 2768.17 | 577 / 578 | 99% | 27.12 | 1143 / 1155 |
ovary | 100% | 1653.11 | 180 / 180 | 98% | 19.59 | 422 / 430 |
bladder | 100% | 1663.76 | 21 / 21 | 97% | 26.04 | 490 / 504 |
liver | 100% | 2244.09 | 226 / 226 | 96% | 17.35 | 388 / 406 |
kidney | 100% | 2219.94 | 89 / 89 | 86% | 11.03 | 774 / 901 |
brain | 87% | 3950.83 | 2305 / 2642 | 74% | 10.73 | 521 / 705 |
adrenal gland | 100% | 3053.78 | 258 / 258 | 50% | 9.50 | 116 / 230 |
adipose | 100% | 1840.86 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 10290.56 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 39.87 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 8.32 | 1 / 1 |
blood vessel | 99% | 2716.94 | 1328 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 1158.59 | 793 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 28.68 | 79 / 80 |
heart | 97% | 1121.75 | 831 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 2293.74 | 892 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 76% | 11.97 | 22 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1905581 | Biological process | positive regulation of low-density lipoprotein particle clearance |
GO_0031623 | Biological process | receptor internalization |
GO_0006898 | Biological process | receptor-mediated endocytosis |
GO_0008203 | Biological process | cholesterol metabolic process |
GO_0090205 | Biological process | positive regulation of cholesterol metabolic process |
GO_0043393 | Biological process | regulation of protein binding |
GO_0048260 | Biological process | positive regulation of receptor-mediated endocytosis |
GO_0071345 | Biological process | cellular response to cytokine stimulus |
GO_0034383 | Biological process | low-density lipoprotein particle clearance |
GO_0090118 | Biological process | receptor-mediated endocytosis involved in cholesterol transport |
GO_1905602 | Biological process | positive regulation of receptor-mediated endocytosis involved in cholesterol transport |
GO_0042982 | Biological process | amyloid precursor protein metabolic process |
GO_1903076 | Biological process | regulation of protein localization to plasma membrane |
GO_1904707 | Biological process | positive regulation of vascular associated smooth muscle cell proliferation |
GO_0030301 | Biological process | cholesterol transport |
GO_0042632 | Biological process | cholesterol homeostasis |
GO_0005886 | Cellular component | plasma membrane |
GO_0055037 | Cellular component | recycling endosome |
GO_0005769 | Cellular component | early endosome |
GO_0005883 | Cellular component | neurofilament |
GO_0009898 | Cellular component | cytoplasmic side of plasma membrane |
GO_0030669 | Cellular component | clathrin-coated endocytic vesicle membrane |
GO_0009925 | Cellular component | basal plasma membrane |
GO_0005829 | Cellular component | cytosol |
GO_0030424 | Cellular component | axon |
GO_0035612 | Molecular function | AP-2 adaptor complex binding |
GO_0001540 | Molecular function | amyloid-beta binding |
GO_0005546 | Molecular function | phosphatidylinositol-4,5-bisphosphate binding |
GO_0050750 | Molecular function | low-density lipoprotein particle receptor binding |
GO_0035591 | Molecular function | signaling adaptor activity |
GO_0030159 | Molecular function | signaling receptor complex adaptor activity |
GO_0035615 | Molecular function | clathrin adaptor activity |
GO_0030276 | Molecular function | clathrin binding |
GO_0035650 | Molecular function | AP-1 adaptor complex binding |
GO_0005515 | Molecular function | protein binding |
GO_0001784 | Molecular function | phosphotyrosine residue binding |
Gene name | LDLRAP1 |
Protein name | Low density lipoprotein receptor adapter protein 1 (Autosomal recessive hypercholesterolemia protein) |
Synonyms | ARH |
Description | FUNCTION: Adapter protein (clathrin-associated sorting protein (CLASP)) required for efficient endocytosis of the LDL receptor (LDLR) in polarized cells such as hepatocytes and lymphocytes, but not in non-polarized cells (fibroblasts). May be required for LDL binding and internalization but not for receptor clustering in coated pits. May facilitate the endocytosis of LDLR and LDLR-LDL complexes from coated pits by stabilizing the interaction between the receptor and the structural components of the pits. May also be involved in the internalization of other LDLR family members. Binds to phosphoinositides, which regulate clathrin bud assembly at the cell surface. Required for trafficking of LRP2 to the endocytic recycling compartment which is necessary for LRP2 proteolysis, releasing a tail fragment which translocates to the nucleus and mediates transcriptional repression (By similarity). . |
Accessions | ENST00000374338.5 Q5SW96 |